Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China
Table 1
Donor demographics.
All ()
D+/R- ()
D+/R+ ()
P value
Age, yr, mean (SD)
0.487
Weight, kg, mean (SD)
0.547
Gender, male, (%)
19 (82.6)
13 (92.9)
6 (66.7)
0.260
Cause of death, (%)
0.498
Intracerebral hemorrhage
14 (60.9)
7 (50.0)
7 (77.8)
Head trauma
5 (21.7)
4 (28.6)
1 (11.2)
Anoxia
4 (17.4)
3 (21.4)
1 (11.1)
CIT, hr, median (IQR)
10 (8-11)
10 (8-10)
10 (8-12)
0.363
WIT, min, median (IQR)
2 (1.42-3)
2 (1.48-3)
2 (1.21-3)
0.948
Donor terminal creatinine, μmol/L, mean (SD)
0.430
Donation after cardiac death, (%)
4 (17.4)
3 (21.4)
1 (11.7)
1.00
Donor viral load (log 10 IU/mL), median (IQR)
5.99 (5.45-6.91)
5.84 (5.46-6.92)
6.37 (5.19-7.35)
0.776
KDPI, %, mean (SD)
0.195
KDRI, mean (SD)
0.195
CIT: cold ischemia time; total time from aortic perfusion to reperfusion of the kidneys. WIT: warm ischemia time; asystole to commencement of aortic perfusion.
